Cargando…
When more is more: the role of additional upfront therapy in pulmonary arterial hypertension
Early combination therapy targeting several relevant pathogenic pathways, including the prostacyclin pathway, is likely to be of benefit to most patients with PAH https://bit.ly/3GisHnA
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841312/ https://www.ncbi.nlm.nih.gov/pubmed/36687364 http://dx.doi.org/10.1183/23120541.00592-2022 |
| Sumario: | Early combination therapy targeting several relevant pathogenic pathways, including the prostacyclin pathway, is likely to be of benefit to most patients with PAH https://bit.ly/3GisHnA |
|---|